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Abstract
While survival rates for localized melanoma are above 98%, metastatic melanoma
proves to be an extraordinarily dreadful disease because of its notoriously poor prognosis
resulting in less than 15% survival within 5 years. This is due to the fact that the disease
is highly resistant to standard cancer therapies. With approximately 40% of melanoma
patients progressing to brain metastasis, a greater understanding of the pathways
mediating melanoma cell invasion into the brain must be achieved. In this study, a
potentially key target often deregulated in melanoma and other cancers, CyclinDependent Kinase 5 (CDK5), will be interrogated for its implications in metastatic
melanoma cell invasion into the brain. Despite the observed deregulation of CDK5 in
various cancers as well as human metastatic melanoma cell lines, there is currently
minimal effort in defining its role in brain metastatic melanoma. This study approaches
this problem in an innovative way by exploring Neurotrophin Receptors (NTR) signaling
pathways involving CDK5. Specifically, activated Neurotrophin Receptors induce EGR1, thus transcribing p35 and activating its obligate partner CDK5. Considering CDK5 is
implicated in a variety of cellular processes such as survival and invasion, this pathway
supports our central hypotheses that activation of CDK5 through Neurotrophin (NT)
signaling is vital in melanoma cell invasion into the brain. In order to test this hypotheses,
a transwell invasion assay utilizing human melanoma cells was used in order to mimic
melanoma metastasis into a brain micro-environment in vitro. In order to implicate
CDK5 in this study, neurotrophin induced invasion of human metastatic melanoma cells
with wild-type expression of CDK5 were compared to cells with drug inhibited CDK5 as
well as lentivirally transduced CDK5 knockout cells. Upon NT stimulation, metastatic
melanoma cells containing active CDK5/p35 demonstrated a higher propensity to invade
into the brain micro-environment. Moreover, simultaneous stimulation of metastatic
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melanoma cells by multiple members of the neurotrophin family were shown to
synergistically enhance invasion ability into a brain micro-environment when compared
to stimulation by a single type of neurotrophin.
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Introduction
In order to understand the purpose and data generated from this study, various
pieces of background information must be clearly laid out. In general, this introductory
section briefly explains the current treatment options for patients with brain metastatic
melanoma (BMM). From here, the potentially therapeutic target named CyclinDependent Kinase 5 (CDK5) will be described with regards to its role in metastatic
melanoma that is supported by existing research. The next part of this introductory
section details a family of proteins called neurotrophins that existing research shows may
have a role in melanoma brain metastases. Finally, this introductory section will conclude
by tying CDK5 to neurotrophins in the context of metastatic melanoma in order to set the
stage for the experiments that compose this study.
Current Treatments for Patients with Brain Metastatic Melanoma
Over the past 50 years, the annual mortality due to melanoma in humans has
increased more than any other form of cancer1. While survival rates for localized
melanoma are above 98%, metastatic melanoma proves to be an extraordinarily dreadful
disease because of its notoriously poor prognosis at less than 15% survival over 5 years
in addition to the tendency of this disease to resist standard cancer therapy regiments2.
One common site of metastasis observed in human melanoma is the brain, with
approximately 40% melanoma patients progressing to brain metastatic melanoma
(BMM)3. In order for brain metastasis to occur, melanoma cells must travel from the
primary tumor site, migrate to the brain, invade across the blood brain barrier, and
survive long enough to induce angiogenesis that will allow tumor cell proliferation to
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occur in the brain tissue4. Only 0.01%-0.03% of melanoma cells will metastasize to any
target organ, thus illustrating that a small proportion of cells can lead to immense
problems within the body5-9. Currently, the primary treatment option for BMM patients is
surgical resection, which carries the risk of damaging healthy brain tissue and oftentimes
does not improve patient prognosis to a significant degree4. Furthermore, standard cancer
treatments such as chemotherapy typically yield low response10. Recently, targeted
therapies involving inhibition of key signaling intermediates in melanoma metastasis
have shown promising results, but are often hindered due to toxicity4. One example of
targeted therapies for BMM can be seen through BRAF inhibitors. The BRAF oncogene
harbors a mutation in roughly 65% of melanoma patients, leading to constitutive
activation of the MEKERKEGF-1 pathway, and thus upregulation of p35, ultimately
leading to constitutive activation of CDK5. BRAF pathway inhibitors such as dabrafenib
and vemurafenib have been tested in a clinical setting with some success. Specifically,
the BRAF inhibitor dabrafenib showed similar response in patients with and without prior
treatment, indicating BRAF inhibition as a viable option for coupled treatments. In
addition, the side effects of dabrafenib were relatively limited and included primarily
fatigue and nausea. In this regard, certain BMM cases such as those with extensive extracranial metastasis may qualify for initial BRAF inhibition followed by surgical resection.
However, an additional limitation for surgical resection is the necessary use of
corticosteroids following the procedure, possibly leading to the impairment of coupled
immunotherapeutic treatments. Even following surgical resection, patient prognosis is
still poor and the procedure carries the potential to damage the brain. However,
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treatments such as BRAF inhibition that can suppress tumor growth and allow for a more
successful surgical resection demonstrate a promising avenue to pursue.
Whole brain radiotherapy is used to supplement or even replace the
surgical procedure, although relying on whole brain radiotherapy as the primary
treatment option is often reserved for cases involving larger tumors (>3cm) or an
abundance of metastatic sites in the brain (>3)4. If possible, targeted radiotherapy is used,
limiting the damaging effects to the brain incurred in whole brain radiotherapy.
Patients with BMM show poor response to standard chemotherapy due to a
variety of factors that are not well understood. This may be due to the inability of the
treatment to penetrate the blood-brain-barrier as well as tumor cell resistance to apoptosis
via paracrine signaling from astrocytes near the tumor site11-12. Even those
chemotherapies that are proven to penetrate the blood-brain-barrier are hampered by low
response rates and short duration of response. However, chemotherapy coupled with
whole brain radiotherapy has shown indications of improved patient prognosis.
Recently, immunotherapies have been shown to be relatively effective and safe in
treating human metastatic melanoma. One such example, ipilimumab, functions to
potentiate anti-tumor response and has been shown to be relatively effective in treating
asymptomatic cases of BMM. In relation to this, patients with BMM who display higher
levels of vascular endothelial growth factor (VEGF) in the blood have a poor response to
the immunotherapy ipilimumab4. This is due to the fact that high levels of VEGF
promotes angiogenesis and suppresses the anti-tumor response of immune cells, a process
that is needed in order for tumors in the brain to grow. As a result of this, antiangiogenics
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have been considered as a potential treatment option for patients with BMM. However,
up to one fifth of patients treated with antiangiogenics experience hemorrhaging in
clinical trials.
Overall, it is clear that current treatment options for patients with BMM leave a
lot to be desired. However, the promise that novel treatments such as those seen with
BRAF inhibitors demonstrate that downstream effectors in the BRAF pathway may prove
to be worthwhile therapeutic targets. One such target is CDK5. This kinase has been
implicated as a relevant target in a variety of cancers, yet has not been established as a
therapeutic target for patients with BMM.
Cyclin-Dependent Kinase 5 in the Context of Metastatic Melanoma
When CDK5 was first studied, it was believed to be implicated mostly in neuronal
function and development. However, numerous studies have since shown that this kinase
is expressed in all tissues and plays a role in an extraordinary amount of disease
pathologies and cell processes including but not limited to cell cycle, growth, migration
and invasion. In fact, evidence supports that CDK5 is involved in both tumor
development as well as metastatic processes. Not surprisingly then, CDK5 has been
shown to be upregulated in numerous cancers. Specifically to melanoma, one study of 45
patients revealed an average of over a 21-fold increase in CDK5 expression in the tumor
tissue 13. To compound this, normal skin and nevus cells show no expression of CDK5,
showing that melanoma tumor formation accompanies a rise in expression of CDK5 14.
Melanoma cells have been shown to be responsive to CDK5 inhibition. Specifically,
mouse models of melanoma have demonstrated reduced tumor growth in cohorts treated
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with dinaciclib, a small molecule CDK inhibitor, when compared to cohorts not treated
with a CDK inhibitor 15. However, the utility of CDK5 inhibitors in treating BMM is not
yet clear.
Neurotrophins in the Context of Metastatic Melanoma
Just over 25 years ago, nerve growth factor (NGF) was identified as a factor for
neuronal survival16. This was the first in a family of survival factors that would go on to
be classified as neurotrophins. However, not all neuronal populations were responsive to
NGF, and thus the search for other factors led to the isolation additional members of this
family of proteins; NGF, brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), and neurotrophin-4 (NT-4). These four neurotrophins are the only four found in
mammals. Although neurotrophins are implicate in a variety of processes, this study is
concerned primarily with the established role of neurotrophins in cell survival and
differentiation17. These effects are due to pathways activated by the interaction between
neurotrophins and several different cell-surface receptors that specifically bind one or
more member in the neurotrophin family. There are two separate classes of these cellsurface receptors; the Trk family of receptors, which bind with higher affinity and
specificity, and the p75 neurotrophin family receptor (p75NTR), which binds with low
affinity and specificity18. While the p75NTR binds all mammalian neurotrophins, the Trk
family of receptors, which includes TrkA, TrkB, and TrkC) bind only specific
neurotrophins. Particularly, TrkA binds Nt-3 and NGF, TrkB binds BDNF, NT-3, and
NT-4, and TrkC binds NT-3.
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Although the role of neurotrophins was originally studied in the context of
neuronal populations, neurotrophins also function in a variety of other tissues, namely in
the skin. Evidence shows that these proteins function both in both an autocrine and
paracrine manner in the skin, suggesting a probable role in the invasive capacity of
metastatic melanoma. Not only have studies shown that neurotrophins promote
melanoma cell survival, but also brain tissue adjacent to brain tumor cells secrete
neurotrophins. Moreover, neurotrophins also induce cellular production of heperanase in
melanoma cells, lending to brain invasive capacity19.
Neurotrophins and CDK5 in Metastatic Melanoma
The skin and nervous system share a common neuroectodermal origin, supporting
the possibility that melanoma has a high propensity to invade the brain because it
provides a favorable environment for metastatic melanoma cells to thrive. However, the
role of neurotrophins in metastatic melanoma has been studied relatively little compared
to other cancers derived from the neural crest, despite the fact that cancers of this origin
share oncogenic pathways 20, 21. One such pathway can be seen in Figure 1. This pathway
demonstrates an interconnection between neurotrophin signaling and CDK5 expression
mediated by a variety of intermediates. In this way, it can be seen that stimulation of
metastatic melanoma cells by neurotrophins can lead to increased invasion capacity via
up-regulation of the obligate activator of CDK5 named p35. The following experiments
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seek to elucidate this pathway and establish CDK5 as a promising therapeutic target in
brain metastatic melanoma.

Figure 1 depicts a cartoon illustration of a NTR signaling pathway.
Notably, NT binds NT‐R, causing induction of EGR‐1 and
transcription of the CDK5 activator p35.
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Methods
In order to implicate CDK5 in the melanoma brain metastasis, we planned two
experiments involving reduction of CDK5 activity in metastatic melanoma cells for use
in Matrigel transwell assays that mimic a brain micro-environment.
Experiment 1
The purpose of the first experiment was to demonstrate that the invasive capacity
human metastatic melanoma cells into a brain micro-environment is proportional to
CDK5 activity. In other words, higher CDK5 activity results in a higher propensity for
invasion into a brain micro-environment. In order to accomplish this aim, a CDK5
inhibitor known as roscovitine was
used in various concentrations to
reduce CDK5 activity. The structure
of roscovitine, which can be seen in
figure 2, is a purine analog and thus
competes for the ATP binding pocket
on CDK5. By blocking CDK5 from
binding ATP, the kinase loses its
phosphorylating ability and is thus inactive. A
cross-section of a single well in the 24 transwell

Figure 2 shows the chemical
structure of the CDK5 inhibitor
Roscovitine. This drug functions by
occupying the ATP binding pocket

plate that was used for this assay can be seen in figure 3. Each well in the transwell plate
contains two halves which are separated from one another by a cell permeable Matrigel
membrane. This Matrigel membrane contains structural proteins that function as an in
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vitro model of a blood brain barrier. Cells are able
to permeate this membrane by chemotactically
migrating through 8 micron pores in the Matrigel
in response to a chemoattractant contained in the
bottom half of the transwell. In experiment 1, the
top half of each well was seeded in serum-free
Figure 3 depicts a cross‐section of
a single well in the transwell plate
used for experiment 1. Each well is
separated by a Matrigel
membrane. In the top half of each
well are confluent WM9 CDK5WT
cells +/‐ Roscovitine. In the bottom
half of each well, either NCM or
NBM functions as a

RPMI media at a density of 2x105 WM9 cells per
well with wildtype CDK5 expression (CDK5WT).
Then, Roscovitine was introduced into the top half
of the well in various concentrations (0µM, 1µM,
5µM, and 10µM). At the same time, either neural
conditioned media (NCM) of neurobasal media

(NBM) was added to the bottom of each well. NCM is conditioned by primary neuronal
cells isolated from p0 stage mice. Thus, NCM contains all sorts of molecules, namely a
host of neurotrophins including NT-3, NT-4, NGF, and BDNF. On the other hand, NBM
is the essential media for neuronal cell culture and contains no cytokines such as
neurotrophins. After the WM9 CDK5WT cells were seeded and both the roscovitine and
either NCM or NBM were added, the transwell plate was set an in incubator and the
assay was allowed to progress for 17 hours. After this time lapse, any cells that were able
to migrate across the Matrigel membrane adhered to the bottom of the membrane. This
allowed for these invaded cells to be fixed and stained, allowing for clear visualization
and quantification of the invaded cells. A representative image of an instance of high
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invasion versus an instance of low invasion can be seen in figure 4. After capturing
images of the invaded
cells, the number of
invaded cells was
quantified by cell
counting with the ImageJ
software.

Figure 4 depicts representative images of instances of high
invasion (on the left) versus low invasion (on the right) in a
Matrigel transwell assay.

Experiment 2
Similar to the first experiment described above, the second experiment in this
study utilized a transwell assay mimicking a brain microenvironment in conjunction with
a unique method of knocking down CDK5 expression. In order to reduce CDK5
expression, and therefore CDK5 activity, WM9 human metastatic melanoma cells were
transduced with the pGIPZ lentiviral vector containing CDK5shRNA for gene
knockdown, GFP for transduction tracking, and a puromycin resistance marker to allow
for specific selection of successfully transduced cells. In order to accomplish this,
plasmids from E.Coli expressing CDK5 were isolated via MaxiPrep. Then 293T
packaging cells were plated at 1x106 cells per 10cm plate. After the 293T cells were
seeded, a transfection mix including the isolated CDK5 plasmids were added along with
shRNA, PEI, and serum free media. This combination allowed for the 293T cells to
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produce a viral supernatant containing lentiviral particles with CDK5shRNA, GFP, and
puromycin resistance markers. After overlaying the transfection mix on the medium of
each plate containing 293T packaging cells for 40 hours, the viral supernatant was
collected. 1ml of viral supernatant
and 3µL of Polybrene were added
with to each well in a six well plate
that was seeded with 4x105 WM9
human metastatic melanoma cells.
After 40 hours of incubation, the
WM9 cells were observed for GFP
Figure 5 depicts an image of WM9 cells expressing
GFP in nearly every cell; a preliminary indication of
high efficiency lentiviral transduction.

expression; an indication of
successful transduction. Figure 5

shows a representative image of an instance of high lentiviral transduction efficiency.
Finally, cells were selected with
puromycin and the successful
transduction of CDK5shRNA into the
WM9 cells was confirmed via western
blotting.
Following lentiviral transduction,
WM9 CDK5shRNA cells were utilized in
a transwell assay similar to the one
described in experiment 1. Figure 6 depicts
a schematic illustrating the design of the

Figure 6 depicts the conditions that were
used for the transwell assay in experiment 2.
In the top half of each well, WM9 CDK5shRNA
or WM9 shLuc (control) cells were seeded.
The bottom half of each well contained either
NBM, NCM, or NBM + NGF)
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transwell assay used in experiment 2. In this transwell assay, similar methods of
preparation were used compared to those used in experiment 1. However, the top half of
each well was seeded with either WM9 CDK5shRNA or WM9 shLuc cells, which
functions as a control vector. In the bottom half of each well, NCM, NBM, or NBM +
NGF was added as a chemoattractant. Methods for quantification of invaded cells were
analogous to those seen in experiment 1.
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Results
Experiment 1
The results from the transwell assay described previously for experiment 1 can be
seen in Figure 7.

Relative Number of
Invaded Cells

Relative Invasion Ability of WM9 CDK5WT Cells At
Various Roscovitine Concentrations
1
0.8

1.0

0.88

0.6

0.5
0.25

0.4

0.3

0.2
0
NCM

NCM + 1µm
Roscovitine

NCM + 5µm
Roscovitine

NCM + 10µm
Roscovitine

NBM

Figure 7 depicts the results from experiment 1.

The vertical axis represents the number of cells that successfully invaded into the
brain micro-environment relative to each condition. The highest invasion was seen in the
case of NCM as a chemoattractant with no roscovitine added, and thus this condition was
set at 1.0. Increasing concentrations of roscovitine resulted in progressively lower levels
of invasion. Relative to the no roscovitine condition, treatment with 1µM roscovitine
resulted in a 12% decrease in invasion, treatment with 5µM roscovitine resulted in a 50%
decrease in invasion, and treatment with 10µM roscovitine resulted in a 75% decrease in
invasion. NBM was used as a control and demonstrated 70% lower invasion when
compared to NCM with no roscovitine.
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Experiment 2
The results from the lentiviral transduction and subsequent transwell assay
described in experiment 2 are depicted in Figures 8 and 9, respectively.

Figure 8 depicts the Western
Blotting data following lentirviral
transduction of WM9 cells with
CDK5shRNA.

Figure 9 depicts the results from
the transwell assay described in
experiment 2.

As can be seen in Figure 8, lentiviral transduction of the WM9 cells with
CDK5shRNA resulted in a severe decrease in CDK5 expression compared to the control.
Thus, the WM9 CDK5shRNA cells demonstrated a significantly reduced invasion ability
in the transwell assay regardless of the chemoattractant used, as can be seen in Figure 9.
Additionally, the condition in the transwell assay utilizing NCM as a chemoattractant
showed the highest invasion ability. Notably, conditions utilizing only NBM as a
chemoattractant showed reduced invasion compared to conditions utilizing NBM + NGF
as a chemoattractant.
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Discussion
Ultimately, the data generated from both experiments 1 and 2 support our central
hypotheses that CDK5 is a vital mediator of WM9 metastatic melanoma cell invasion
into a brain micro-environment in response to neurotrophin stimulation. In experiment 1,
drug induced inhibition of CDK5 showed significant reduction in the ability of WM9
cells to invade a brain micro-environment. Thus, this data provides evidence that CDK5
is a promising therapeutic target for patients with BMM, particularly considering that
neurotrophins play a significant role in the event of brain metastasis. It is possible that
roscovitine induced inhibition of CDK5 effects cell viability moreso than invasion
propensity, however this effect would still be beneficial to patients with BMM if it could
be targeted specifically to melanoma cells.
Data generated from experiment 2 provides further evidence that CDK5 is a
relevant therapeutic target for patients with BMM. If tumor cells could be specifically
transduced with CDK5shRNA, additional avenues for treatment options for BMM may
open. On a separate note, the data generated from experiment 2 supports existing research
that neurotrophins are responsible for melanoma brain metastasis. This notion is derived
from the fact that the chemoattractant of NBM + NGF resulted roughly twice the invasion
compared to just NBM as a chemoattractant. Thus, neurotrophins must be at least
partially responsible for promoting metastatic melanoma cells to invade a brain
microenvironment. Additionally, this data indicates that neurotrophin induced invasion
ability is bolstered when multiple types of neurotrophins, such as both NGF and NT-3,
stimulate the cell.
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Future studies should seek to further elucidate intermediates in the BRAF
signaling pathway and their role in brain metastatic melanoma. In this way, additional
promising therapeutic targets may be revealed. Furthermore, further studies should utilize
a brain metastatic melanoma model in mice so that the relevance of CDK5 in BMM can
be explored in vivo, thus taking another step towards bringing new treatment options to
the clinic for patients with this dreadful disease.
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